治疗黑色素瘤靶向药获批进入中国,专家提醒:不要随便点痣

2017-08-10 董子畅 中国新闻网

治疗“癌中之王”黑色素瘤的靶向药日前获批进入中国,并被纳入《中国黑色素瘤诊治指南(2017版)》,标志着国内黑色素瘤治疗迈入靶向时代。

治疗“癌中之王”黑色素瘤的靶向药日前获批进入中国,并被纳入《中国黑色素瘤诊治指南(2017版)》,标志着国内黑色素瘤治疗迈入靶向时代。

黑色素瘤是皮肤肿瘤中恶性程度最高的瘤种,癌细胞会逐步渗透到皮肤和粘膜中,最终到达血管或淋巴通道,并迅速传播到整个身体和主要器官。一旦发生转移,患者的5年生存率仅为4.6%。由于死亡率高、转移率高、治疗难度大,黑色素瘤被称为“癌中之王”。

据悉,中国黑色素瘤发病率为0.6/10万,属于罕见病,但近年来呈上升趋势。北京大学肿瘤医院副院长、中国抗癌协会临床肿瘤学协作专业委员会(CSCO)黑色素瘤专家委员会主任委员郭军日前在北京表示,与西方不同,中国多发的黑色素瘤特殊类型恶性程度更高。“西方人黑色素瘤多分布在皮肤浅表(称为皮肤型),而中国约50%的黑色素瘤分布于四肢末端的皮肤(称为肢端型),更容易发生移行转移。另外,还有20%为粘膜型,如消化道、鼻腔等,其恶性程度更高,预后很差,而白种人中这一类型患者不到1%。”

究竟是什么导致了黑色素瘤产生,中华医学会肿瘤分会副主委林桐榆介绍,白种人的黑色素瘤多与紫外线过度照射有关,而中国黑色素瘤发病与紫外线照射关系不大,大多与不恰当处理有关,如擅自使用激光、绳勒、盐腌和刀剪等。

“中国患者对黑色素瘤的知晓率仍然很低,大部分患者发现时已是中晚期,错过了最佳治疗时机。”林桐榆表示,有些爱美女性喜欢擅自去美容机构点痣,但她们无法辨别究竟是良性色素痣还是早期的黑色素瘤,若贸然进行了激光或冷冻处理,很可能把原本长在表皮的黑色素瘤带入真皮,引发快速转移。

他建议,当发现色素痣不对称、颜色变化、边缘不整齐、逐渐变大或感觉异常时,应及时就医,千万不能自行处理。一经诊断为黑色素瘤,应及早采取规范治疗。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1680431, encodeId=33741680431e6, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jul 14 21:53:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487626, encodeId=e16b148e6269d, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558826, encodeId=6878155882680, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564835, encodeId=4388156483547, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2018-07-14 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1680431, encodeId=33741680431e6, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jul 14 21:53:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487626, encodeId=e16b148e6269d, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558826, encodeId=6878155882680, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564835, encodeId=4388156483547, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
    2017-08-12 yese
  3. [GetPortalCommentsPageByObjectIdResponse(id=1680431, encodeId=33741680431e6, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jul 14 21:53:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487626, encodeId=e16b148e6269d, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558826, encodeId=6878155882680, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564835, encodeId=4388156483547, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1680431, encodeId=33741680431e6, content=<a href='/topic/show?id=9e5c86e0712' target=_blank style='color:#2F92EE;'>#色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86707, encryptionId=9e5c86e0712, topicName=色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=343027846633, createdName=sunylz, createdTime=Sat Jul 14 21:53:00 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487626, encodeId=e16b148e6269d, content=<a href='/topic/show?id=ae23e118228' target=_blank style='color:#2F92EE;'>#痣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71182, encryptionId=ae23e118228, topicName=痣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21678344192, createdName=yese, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558826, encodeId=6878155882680, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564835, encodeId=4388156483547, content=<a href='/topic/show?id=e27610332666' target=_blank style='color:#2F92EE;'>#黑色素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103326, encryptionId=e27610332666, topicName=黑色素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=150614999302, createdName=cqlidoudou, createdTime=Sat Aug 12 05:53:00 CST 2017, time=2017-08-12, status=1, ipAttribution=)]

相关资讯

PNAS:干细胞释放的溶瘤性单纯疱疹病毒治疗脑转移性黑色素瘤

最近,FDA批准了免疫原性的溶瘤病毒,开辟了治疗晚期黑色素瘤的新时代。但是,研究表明,约有50%的黑色素瘤患者会发展为脑转移。对于这部分病人,目前还没有有效的治疗手段。

J Am Acad Dermatol:良性肢端黑色素瘤的临床病理学特征有哪些?在成人和儿童患者中有何区别?

肢端黑色素瘤是黑色素瘤的一种亚型,是我国黑色素瘤中最常见的亚型(约占50%)。最常见的原发部位为足底、足趾、手指末端及甲下等部位。7月发表在J Am Acad Dermatol上的一篇研究,来自朝鲜的研究人员对良性肢端黑色素瘤的临床病理学特征进行了探讨,研究主要内容如下:背景:目前的研究对良性肢端黑色素瘤(BAMN)的临床病理学特征仍然知之甚少。目的:为了确定良性肢端黑色素瘤的临床病理特征。方法:

J Am Acad Dermatol:磷酸二酯酶5抑制剂与黑色素瘤进展的风险增加相关(Meta分析)

5型磷酸二酯酶抑制剂是一种抑制磷酸二酯酶活性的药物。选择性的磷酸二酯酶5抑制剂在男性勃起功能障碍等疾病中,具有广泛的应用前景。但是,来自美国印第安纳州的研究人员探讨了5型磷酸二酯酶抑制剂与黑色素瘤风险之间的相关性,并将结果发表在7月的J Am Acad Dermatol上,研究摘要如下:背景:5型磷酸二酯酶(PDE5)抑制剂和黑色素瘤的风险之间的相关性是有争议的。目的:旨在量化PDE5抑制剂的使用

盘点:近期黑色素瘤重要研究进展一览

黑色素瘤,又称恶性黑色素瘤,是来源于黑色素细胞的一类恶性肿瘤,常见于皮肤,亦见于黏膜、眼脉络膜等部位。黑色素瘤是皮肤肿瘤中恶性程度最高的瘤种,容易出现远处转移。早期诊断和治疗因而显得尤为重要。本文梅斯医学小编进近期有关黑色素瘤指南共识及研究进行汇总,与大家一同分享。【1】Mol Cancer Therap:新型药物或能有效阻断90%的黑色素瘤转移日前,刊登在国际杂志Molecular Canc

J Am Acad Dermatol:黑色素瘤局部广泛切除术后切缘阳性或可疑阳性的危险因素有哪些?

对所有恶性肿瘤的手术切除边缘已有了反复的讨论。皮肤黑色素瘤术后的切缘阳性的风险多大?危险因素有哪些?7月发表在J Am Acad Dermatol上的一项研究对其进行了探讨,研究的主要内容如下:背景:局部广泛切除术(WLE)后的切缘阳性或可疑阳性会恶化皮肤黑色素瘤外科治疗后的结局。目的:旨在识别皮肤黑色素瘤患者行局部广泛切除术后,切缘阳性或可疑阳性的频率和风险因素。方法:这是一项回顾性、单中心,包

J Am Acad Dermatol:PDL1表达与黑色素瘤的侵袭性和进展相关

程序性死亡配体1(programmed death ligand 1,PDL1)、CD8和叉头样转录因子3(FoxP3)的表达对结缔组织增生性恶性黑色素瘤的预后作用仍未阐明。因此,来自美国的研究人员对其进行了探讨,并将研究结果发表在7月份的J Am Acad Dermatol上,研究的主要内容如下:研究人员在66名结缔组织增生性恶性黑色素瘤患者中探讨了PDL1、p53和Ki-67的表达与CD8 +